MedTrace Logo

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Axatilimab Monotherapy in Japanese Participants With Recurrent or Refractory Active Chronic Graft-Versus-Host Disease

NCT06263478 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2026-01-07

No results posted yet for this study

Summary

This study will be conducted to determine the clinical efficacy of axatilimab in Japanese participants with chronic graft-versus-host disease (cGVHD).

Conditions

  • Chronic Graft-versus-host-disease

Interventions

DRUG

INCA034176

IV infusion

Sponsors & Collaborators

  • Incyte Biosciences Japan GK

    lead INDUSTRY

Principal Investigators

  • Incyte Medical Monitor · Incyte Corporation

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
6 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-07-30
Primary Completion
2025-08-06
Completion
2027-03-30
FDA Drug
Yes

Countries

  • Japan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06263478 on ClinicalTrials.gov